NCT03180840 - Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 10, 2017

Primary Completion Date

August 1, 2020

Study Completion Date

August 1, 2020

Conditions

Fabry Disease

Interventions

BIOLOGICAL

Pegunigalsidase alfa

Pegunigalsidase alfa 2 mg/kg every 4 weeks

Trial Locations (14)

2100

Rigshospitalet, Copenhagen

2650

UZ Antwerpen, Edegem

5021

Helse Bergen HF Haukeland Universitetssykehus, Bergen

22030

O & O Alpan, Fairfax

30322

Emory University School of Medicine, Atlanta

35294

UAB Medicine, Birmingham

49525

Infusion Associates, Grand Rapids

52242

University of Iowa Hospitals and Clinics, Iowa City

75226

Institute of Metabolic Disease, Dallas

84132

University of Utah Hospital & Clinics, Salt Lake City

120 00

Fakultní poliklinika Všeobecné fakultní nemocnice v Praze, Prague

Unknown

"Azienda Ospedaliera Universitaria Federico II", Napoli

CB2 0QQ

Addenbrooke's Hospital, Cambridge

NW3 2QG

The Royal Free Hospital, London

All Listed Sponsors

collaborator

Chiesi Farmaceutici S.p.A.

INDUSTRY

lead

Protalix

INDUSTRY